BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

Summary by AI BETAClose X

BioNTech reported second quarter 2026 revenues of €105.6 million, with adjusted R&D expenses of €477.1 million and adjusted SG&A expenses of €197.8 million, while maintaining a strong financial position with €16.6 billion in cash and investments. The company revised its full-year 2026 revenue guidance downwards to €1.6–1.9 billion, citing softer COVID-19 vaccine demand and delayed milestone revenues, but maintained its adjusted SG&A expense guidance of €700–800 million and adjusted R&D expense guidance to €2.0–2.3 billion. Significant pipeline progress includes the initiation of six pivotal trials for oncology candidates, with encouraging efficacy data for pumitamig in non-small cell lung cancer, and the European Commission approval of a new variant-adapted COVID-19 vaccine. Guido Oelkers is appointed as the new CEO, effective by February 1, 2027.

Disclaimer*

UK 100

Latest directors dealings